<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jessica Levi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert C O'Reilly, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn C Isaacson, MD, FAAP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H191200257"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic suppurative otitis media (CSOM) is one of the most common childhood infectious diseases worldwide and is a leading cause of hearing impairment in resource-limited settings. It is less frequently seen in resource-abundant settings. It is characterized by chronic drainage from the middle ear associated with tympanic membrane (TM) perforation (<a class="graphic graphic_picture graphicRef91415" href="/d/graphic/91415.html" rel="external">picture 1</a>). CSOM is usually preceded by an episode of acute otitis media (AOM).</p><p>The treatment, complications, and prevention of CSOM are reviewed here. The clinical features and diagnosis of CSOM are discussed in detail separately. CSOM in the setting of tympanostomy tubes is also reviewed separately. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6295.html" rel="external">"Tympanostomy tube otorrhea in children: Causes, prevention, and management"</a>.)</p><p>AOM, otitis media with effusion, and cholesteatoma in children and acute and chronic otitis media in adults are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6872.html" rel="external">"Acute otitis media in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15312.html" rel="external">"Chronic otitis media and cholesteatoma in adults"</a>.)</p><p></p><p class="headingAnchor" id="H191200287"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>We suggest aural toilet plus empiric topical antibiotics for initial therapy. The primary goal of treatment is eradicating infection and preventing complications, which is achieved by producing a dry ear. Longer term goals include healing/repair of the tympanic membrane (TM) and improvement in hearing [<a href="#rid1">1</a>].</p><p>Educating caregivers on the proper administration of topical antibiotics and other measures that reduce recurrence is an important aspect of initial management. One study found that families randomized to an educational program regarding the placement of ear drops as well as decreasing risk factors had a higher cure rate than those given antibiotics alone at one, three, and six months [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H191200293"><span class="h2">Aural toilet</span><span class="headingEndMark"> — </span>We suggest aural toilet in combination with a topical quinolone for initial therapy. (See <a class="local">'Ototopical antibiotics'</a> below.)</p><p>Aural toilet is a key component of treatment since it allows the topical antibiotic or antiseptic to truly penetrate to the source of the disease. However, its efficacy is debated, particularly when used as the sole therapy.</p><p>Aural toilet is performed until the ear is consistently dry and free of debris [<a href="#rid3">3</a>]. Techniques include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mopping (the otorrhea is absorbed by a wisp of cotton wool that is wrapped around a probe used for ear wax removal and inserted into the ear canal under direct visualization with a head lamp, otoscope, or microscope)</p><p class="bulletIndent1"><span class="glyph">●</span>Ear wicking</p><p class="bulletIndent1"><span class="glyph">●</span>Gentle syringing</p><p class="bulletIndent1"><span class="glyph">●</span>Suctioning</p><p></p><p>Careful suctioning of the ear canal to remove gross amounts of debris can be accomplished in the office. The preferred method is suctioning under the microscope (typically performed by an otolaryngologist) because it also allows for a better examination to help rule out cholesteatoma. Wick placement, if there is sufficient canal edema to hold the wick in place, can also be performed by a clinician and then removed at a later date by either the patient/caregiver or the clinician.</p><p>There are no standards regarding how often aural toilet should be performed. The frequency of suctioning depends on how fast the debris accumulates and how easy it is for the patient to return to the office. Some otolaryngologists advise performing aural toilet at least two to three times per week [<a href="#rid4">4</a>], but this frequency may not be necessary in less severe cases. Daily aural toilet may be beneficial in patients who have failed previous therapy [<a href="#rid5">5</a>].</p><p>Limited data suggest that aural toilet alone is not as effective as topical or systemic antibiotic therapy alone or in combination with aural toilet. Observational studies suggested that otorrhea may resolve with aural toilet in as many as 60 to 80 percent of cases [<a href="#rid6">6,7</a>]; however, results of randomized trials contradict these findings [<a href="#rid1">1,8,9</a>]. In a randomized trial of 524 children with CSOM assigned to combination therapy (consisting of aural toilet plus topical and systemic antibiotics plus topical steroids), aural toilet alone, or no specific treatment, 51 percent of patients in the combination therapy group had resolved otorrhea by 16 weeks compared with only 22 percent in the other two treatment groups [<a href="#rid1">1</a>]. In a similar small randomized trial, all 21 children with CSOM treated with aural toilet and intravenous (IV) antibiotic improved, whereas only 1 of 12 patients who received aural toilet alone had resolution of otorrhea [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3111690317"><span class="h2">Alternatives to aural toilet in resource-limited settings (antiseptics)</span><span class="headingEndMark"> — </span>In resource-limited settings, suction and other equipment required for aural toilet are often unavailable. In addition, it may be challenging for patients to travel back and forth from the clinician's office for the initial or subsequent cleanings. Alternative irrigation solutions are frequently used to treat CSOM in these settings.</p><p>In our practice, when an alternative to aural toilet is needed, we typically use a 50% peroxide solution in sterile water for clearing the ear canal prior to placement of topical therapies. However, there are no published data on this approach. We typically instill approximately five drops of the solution into the affected ear, let it sit in the ear canal for at least 30 seconds if possible, and then have the patient tip their head to let the solution and debris drain out.</p><p>Other commonly used agents include:</p><p class="bulletIndent1"><span class="glyph">●</span>Burrow's solution (13% <a class="drug drug_pediatric" data-topicid="13383" href="/d/drug information/13383.html" rel="external">aluminum acetate</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Zinc</p><p class="bulletIndent1"><span class="glyph">●</span>Boric acid</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="87235" href="/d/drug information/87235.html" rel="external">Acetic acid</a> (vinegar)</p><p class="bulletIndent1"><span class="glyph">●</span>Povidone-iodine</p><p></p><p>Limited evidence suggests that these agents may be more effective than no treatment, but it is uncertain if one agent is superior to others [<a href="#rid10">10-15</a>]. Although these agents are widely used, the potential for ototoxicity should be kept in mind and discussed with patients, especially if long-term or frequent use is planned. The potential for ototoxicity with these agents is uncertain; however, data from animal studies suggest ototoxicity may occur with povidone-iodine [<a href="#rid16">16</a>]. In addition, some of these agents (eg, boric acid and <a class="drug drug_pediatric" data-topicid="87235" href="/d/drug information/87235.html" rel="external">acetic acid</a>) can irritate the middle ear, which may limit compliance.</p><p class="headingAnchor" id="H191200299"><span class="h2">Ototopical antibiotics</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> otic solution (five drops three times a day) or <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> otic solution (0.25 mL single-dose container twice daily) for two weeks in addition to aural toilet. (See <a class="local">'Aural toilet'</a> above.)</p><p>Treatment with topical antibiotic therapy is preferred over systemic antibiotic therapy for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral antibiotics may have limited efficacy in some patients with CSOM because of tissue damage, inflammation, scarring, and limited vascularization of the middle ear mucosa. (See <a class="local">'Oral antibiotics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic side effects are minimized with topical antibiotic therapy, particularly in children [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In most cases, systemic antibiotics alone or in combination with topical preparations do not improve treatment outcomes over topical antibiotics alone [<a href="#rid18">18,19</a>].</p><p></p><p>Cost-effectiveness studies have shown that aural toilet plus drops are more cost effective than other treatments [<a href="#rid20">20</a>].</p><p>Fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a>) are effective against many of the gram-positive and gram-negative organisms that cause CSOM and are the most commonly used topical medication for CSOM in the United States. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Microbiology'</a>.)</p><p>Fluoroquinolones are highly effective in treating CSOM, with reported cure rates ranging from 75 to 100 percent [<a href="#rid21">21-24</a>]. Data from randomized clinical trials suggest topical quinolones are more effective than other alternatives, including oral amoxicillin-clavulanic acid, oral <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, and topical aminoglycosides [<a href="#rid18">18,21-23,25,26</a>]. Additional considerations that favor topical fluoroquinolones over topical aminoglycosides include their greater effectiveness against <em>Pseudomonas</em> and lower risk of ototoxicity [<a href="#rid27">27</a>]. However, some <em>Pseudomonas</em> and many methicillin-resistant <em>Staphylococcus</em> <em>aureus</em> (MRSA) isolates are resistant to fluoroquinolones and require culture-directed treatment. (See <a class="local">'Treatment failure'</a> below.)</p><p>With the exception of ototopical <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> and <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, there are no US Food and Drug Administration (FDA)-approved topical antibiotics for use in the presence of a non-intact TM or patent tympanostomy tube. Although non-FDA-approved agents are widely used, including topical aminoglycoside drops, antifungals, and other agents (eg, <a class="drug drug_pediatric" data-topicid="12634" href="/d/drug information/12634.html" rel="external">neomycin</a>/<a class="drug drug_pediatric" data-topicid="12716" href="/d/drug information/12716.html" rel="external">polymyxin B</a>), the potential for ototoxicity should be kept in mind and discussed with the patients, especially if long-term or frequent use is planned [<a href="#rid28">28-30</a>].</p><p class="headingAnchor" id="H191200305"><span class="h2">Ototopical corticosteroids</span><span class="headingEndMark"> — </span>Use of topical corticosteroids (usually in combination with an ototopical antibiotic) is controversial and not well studied. We typically only use a combination drop (antibiotic plus corticosteroid) if granulation tissue is present (<a class="graphic graphic_picture graphicRef107997" href="/d/graphic/107997.html" rel="external">picture 2</a>) [<a href="#rid31">31,32</a>]. A randomized controlled trial in 110 patients with CSOM found no difference in disease resolution among patients treated with combination <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> plus <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> compared with those treated with ofloxacin alone [<a href="#rid33">33</a>]. The use of combination fluoroquinolone plus corticosteroid ototopical therapy in the management of tympanostomy tube otorrhea is discussed separately. (See  <a class="medical medical_review" href="/d/html/6295.html" rel="external">"Tympanostomy tube otorrhea in children: Causes, prevention, and management", section on 'Uncomplicated acute tympanostomy tube otorrhea'</a>.)</p><p class="headingAnchor" id="H191200323"><span class="h1">TREATMENT FAILURE</span></p><p class="headingAnchor" id="H2694257519"><span class="h2">Causes</span><span class="headingEndMark"> — </span>Treatment is considered to have failed if otorrhea continues after approximately three weeks of medical therapy. Causes of failure include resistant organisms, poor adherence to the medical regimen, presence of a cholesteatoma, or underlying immunodeficiency (eg, HIV) [<a href="#rid34">34-37</a>].</p><p>Failure rates of medical treatment vary widely in the literature (from 20 to 80 percent), often depending on the therapy used [<a href="#rid35">35</a>]. The actual failure rate of medical therapy for CSOM may be lower than reported, however, since some patients may have an unrecognized underlying cholesteatoma, a surgical disease that will not resolve with medical treatment. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children"</a>.)</p><p class="headingAnchor" id="H2848276503"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Cultures should be obtained in patients who fail initial therapy, under the microscope directly through the tympanic membrane (TM) perforation since cultures taken from the external auditory canal may be unreliable or misleading [<a href="#rid38">38</a>].</p><p>In addition, treatment failure in patients with good adherence to the medical regimen should prompt evaluation for alternative or additional diagnoses, particularly cholesteatoma. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>If cholesteatoma is suspected, high-resolution computed tomography (CT) of the temporal bone should be obtained. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3196172237"><span class="h2">Management</span></p><p class="headingAnchor" id="H4066345741"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>Patients with treatment failure are treated with culture-directed topical antibiotics in addition to aural toilet. If there is no therapeutic topical option based on the susceptibility patterns of the isolated pathogen, we use oral antibiotics. If the patient fails culture-directed topical or oral therapy, we treat with intravenous (IV) antibiotics. However, some centers advocate surgery rather than IV antibiotics for patients who fail ototopical or oral antibiotic courses. Other experts (including the authors of this topic) believe that middle ear and mastoid surgery should be reserved for children who fail maximal medical therapy (including IV antibiotics) [<a href="#rid39">39</a>] or have recurrent disease over a relatively short period of time (approximately six to eight weeks) [<a href="#rid40">40</a>]. Recurrent disease is discussed below. (See <a class="local">'Recurrent disease'</a> below.)</p><p class="headingAnchor" id="H3357129550"><span class="h3">Topical antibiotics</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">Ofloxacin</a> and <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> otic solutions are the only topical preparations approved by the US Food and Drug Administration (FDA) for use in ears with perforated TMs; thus, use of all other topical antibiotics is off-label for CSOM. As an example, in cases of methicillin-resistant <em>S</em>. <em>aureus</em> (MRSA) that are not sensitive to quinolones, we use <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> ophthalmic solution (25 mg/mL), three drops in affected ear(s) three times a day for up to two weeks, with audiologic monitoring and ear examination at least weekly to ensure hearing is stable and to determine length of therapy [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H608792"><span class="h3">Oral antibiotics</span><span class="headingEndMark"> — </span>We use oral antibiotics in patients who fail initial topical therapy and whose culture results indicate that there is no therapeutic topical antibiotic available. The choice of antibiotic is based on culture results. Oral quinolones (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>) are reserved for cases in which there is no other safe and effective alternative. We typically treat for 14 to 21 days.</p><p>Oral antibiotics may have limited efficacy in CSOM because of tissue damage, inflammation, and scarring, as well as limited vascularization of the middle ear mucosa, which make it difficult for systemic therapy to reach the source of the infection [<a href="#rid4">4,42</a>]. In addition, they have greater potential side effects than do topical antibiotics. However, the available data suggest that oral quinolones may be effective agents in patients who have failed topical therapy and have bacteria resistant to other antibiotics [<a href="#rid43">43,44</a>]. Oral <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> is effective in treating refractory CSOM caused by MRSA and multiple drug-resistant <em>Streptococcus pneumoniae </em>[<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H191200329"><span class="h3">Intravenous antibiotics</span><span class="headingEndMark"> — </span>In patients who fail culture-directed topical or oral therapy (for a minimum of 14 to 21 days), we treat with IV antibiotics. If the patient is in an inpatient setting, or lives close by, frequent aural toilet in the office in conjunction with IV therapy may facilitate clearing of the infection (see <a class="local">'Aural toilet'</a> above). We advise consultation with an infectious disease specialist to help determine the best antibiotic choice in patients who require IV therapy. High resistance rates are seen with IV <a class="drug drug_pediatric" data-topicid="12687" href="/d/drug information/12687.html" rel="external">penicillin G</a> and <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a>, and poor response rates are also seen with <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a> [<a href="#rid46">46,47</a>]. Better response rates are seen with more broad-spectrum antibiotics, such as mezlocillin and <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> [<a href="#rid8">8,47</a>].</p><p><em>Pseudomonas</em> <em>aeruginosa</em> and MRSA are the most commonly identified resistant organisms in CSOM [<a href="#rid7">7,46,48</a>]. <em>P</em>. <em>aeruginosa</em> was most susceptible to <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> and <a class="drug drug_pediatric" data-topicid="13375" href="/d/drug information/13375.html" rel="external">imipenem</a> in one series [<a href="#rid46">46</a>], and <a class="drug drug_pediatric" data-topicid="12949" href="/d/drug information/12949.html" rel="external">aztreonam</a> was as effective against <em>P</em>. <em>aeruginosa</em> as <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> in a small randomized trial (10 of 15 and 13 of 15 patients cured, respectively) [<a href="#rid49">49</a>]. However, ciprofloxacin-resistant <em>P</em>. <em>aeruginosa</em> was identified in all 88 patients (including adults) with CSOM unresponsive to treatment with topical ciprofloxacin in a subsequent study [<a href="#rid50">50</a>]. In vitro testing of these bacterial isolates revealed that nearly all (96 percent) were susceptible to imipenem, whereas &lt;60 percent were susceptible to other antibiotics (including <a class="drug drug_pediatric" data-topicid="12541" href="/d/drug information/12541.html" rel="external">amikacin</a>, <a class="drug drug_pediatric" data-topicid="12708" href="/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a>, and ceftazidime).</p><p>In a series of patients with community-acquired MRSA, all organisms were susceptible to <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> and 90 percent were susceptible to <a class="drug drug_pediatric" data-topicid="12767" href="/d/drug information/12767.html" rel="external">rifampin</a> [<a href="#rid51">51</a>]. In a retrospective study, drainage resolved in 17 of 22 patients treated with teicoplanin and 12 of 15 patients treated with <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> for CSOM with MRSA, which was similar to the rate of improvement seen with aural toilet and irrigation with <a class="drug drug_pediatric" data-topicid="87235" href="/d/drug information/87235.html" rel="external">acetic acid</a> or Burrow's solution [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H191200335"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Surgical options for refractory CSOM include tympanoplasty or tympanomastoidectomy. Patients with bilateral disease can be treated at the same time with bilateral tympanoplasties [<a href="#rid52">52</a>]. We prefer to exhaust all medical options before proceeding with surgical therapy. When possible, we obtain a CT scan in patients who fail medical therapy to evaluate for cholesteatoma prior to surgery since this finding affects the surgical approach (usually mastoidectomy with tympanoplasty is performed rather than tympanoplasty alone).</p><p>Surgical therapy was the mainstay of treatment for CSOM until the mid-1980s [<a href="#rid53">53</a>]. However, its precise role in uncomplicated CSOM without cholesteatoma and exactly which procedure should be performed are controversial. Surgical management of cholesteatoma is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children", section on 'Surgical treatment'</a>.)</p><p>The available data suggest that there is no role for routinely performing mastoidectomy in children with uncomplicated CSOM (ie, without cholesteatoma) [<a href="#rid54">54-56</a>]. Performing a mastoidectomy in addition to tympanoplasty adds cost, time, and potential for complications. In addition, in resource-limited regions where rates of CSOM are highest, access to surgical care can be limited.</p><p>In a retrospective study that included patients with CSOM and dry ears who underwent tympanoplasty only (n = 242), patients with wet ears who underwent tympanoplasty only (n = 53), and patients with wet ears who underwent canal wall up tympanomastoidectomy (n = 28), hearing outcomes and graft success rates were similar in all three groups [<a href="#rid55">55</a>]. Another retrospective study similarly compared patients with CSOM undergoing tympanoplasty with (n = 147) and without (n = 104) mastoidectomy and also found no difference in graft success rate, regardless of preoperative otorrhea or CT scan findings [<a href="#rid56">56</a>].</p><p>The presence or absence of active disease at the time of surgery (ie, wet versus dry ears) and the type of microorganisms isolated in culture do not appear to impact the success rates of tympanoplasty [<a href="#rid57">57-59</a>].</p><p>The role for balloon eustachian tuboplasty at the time of tympanoplasty is uncertain [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H9145523"><span class="h1">RECURRENT DISEASE</span><span class="headingEndMark"> — </span>CSOM is generally a remitting and relapsing disease. In a small number of patients, it is truly chronic, without cessation of symptoms despite therapy.</p><p class="headingAnchor" id="H9146137"><span class="h2">Frequency and risk factors</span><span class="headingEndMark"> — </span>Recurrence is most common during the first several months after initial therapy. The rates of relapse do not appear to be affected by age, duration of ear drainage, specific antibiotic used, or presence of granulation tissue. Recurrence rates are variable, ranging from 15 to 65 percent, probably due in part to the lack of consistency in treatment approaches [<a href="#rid7">7,11,40,44,62-65</a>]. In one study, early recurrence was associated with poorer response to subsequent therapy including antimicrobials and surgery [<a href="#rid63">63</a>].</p><p>One of the main determining factors for recurrence is the status of the tympanic membrane (TM). Even when the perforation is dry and the acute infection has been treated adequately, the patient is at risk for further episodes of suppuration until the TM has healed.</p><p>In a report of 51 children with CSOM who were followed for a median of 4.3 years after initial treatment, &gt;95 percent of patients responded to initial medical therapy; however, nearly one-half had recurrent disease, most of whom cleared with outpatient medical management [<a href="#rid40">40</a>]. Four patients required intravenous (IV) antibiotic therapy and nine required surgery due to either failed initial medical therapy or recurrent disease that did not clear with medical management. Four of these patients required revision surgery, at which time, three were found to have a cholesteatoma.</p><p class="headingAnchor" id="H9146042"><span class="h2">Prevention of recurrences</span><span class="headingEndMark"> — </span>Measures to prevent recurrences of CSOM after successful treatment depend in part on the function of the Eustachian tube, which tends to improve with age. Preventive measures include teaching the patient to keep their ears dry (ie, aural toilet and strict water precautions) and surgical repair of the perforated TM if needed [<a href="#rid39">39</a>]. We prefer these approaches rather than long courses of prophylactic antibiotics, which can make subsequent treatment more difficult if antibiotic resistance develops. (See <a class="local">'Management of recurrent disease'</a> below and <a class="local">'Aural toilet'</a> above.)</p><p class="headingAnchor" id="H3296544674"><span class="h3">Management of recurrent disease</span><span class="headingEndMark"> — </span>We advise strict water precautions for patients with recurrent disease. In addition, the patient should undergo a computed tomography (CT) scan to evaluate for cholesteatoma, if this has not already been performed, since cholesteatoma can present as recurrent otorrhea. We perform tympanoplasty in patients without cholesteatoma who continue to have recurrent disease despite water precautions. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H9146468"><span class="h3">Surgery for persistent tympanic membrane perforation</span><span class="headingEndMark"> — </span>TM perforations often heal with effective treatment of CSOM, and surgery is not required in these cases. As an example, approximately 14 percent of 524 children had healing of the TM by 16 weeks [<a href="#rid1">1</a>] and, in another series, 24 of 32 patients (75 percent) diagnosed with CSOM between the ages of zero and four healed spontaneously by ages 11 to 15 [<a href="#rid66">66</a>].</p><p>We suggest tympanoplasty for patients who have persistent perforation for &gt;6 to 12 months after resolution of CSOM to prevent recurrence. We do not advise routine mastoidectomy in this setting, as discussed above. (See <a class="local">'Surgery'</a> above.)</p><p>For patients with persistent perforation and frequent recurrences of CSOM, surgery reduces the likelihood of subsequent recurrences compared with continued medical management. In one study, the mean time to recurrence in patients treated medically was four months, while for those treated surgically, it was five to seven years [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H191200371"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications include extra- and intracranial spread of infection, persistent hearing loss, and, rarely, death.</p><p class="headingAnchor" id="H9146298"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Complicated CSOM occurs most commonly in adolescents and young adults [<a href="#rid68">68-70</a>]. Several studies have reported that males are at greater risk for complicated CSOM [<a href="#rid68">68,70</a>]. Other risk factors include:</p><p class="bulletIndent1"><span class="glyph">●</span>Low socioeconomic status [<a href="#rid70">70,71</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged symptom duration before seeking medical attention [<a href="#rid36">36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atticoantral type of CSOM [<a href="#rid68">68,72</a>] (see  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Anatomic classification of CSOM'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholesteatoma [<a href="#rid68">68,70,72,73</a>] (see  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection caused by multidrug-resistant bacteria [<a href="#rid36">36</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying HIV infection [<a href="#rid36">36</a>]</p><p></p><p class="headingAnchor" id="H9146378"><span class="h2">Infectious extra- and intracranial complications</span><span class="headingEndMark"> — </span>Extra- and intracranial complications occur when the infection spreads through natural or pathologic bony dehiscences and vascular channels to involve the mastoid, facial nerve, labyrinth, lateral sinus, cerebrospinal fluid, and brain (<a class="graphic graphic_figure graphicRef83204" href="/d/graphic/83204.html" rel="external">figure 1</a>).</p><p>A change in the clinical picture should alert the clinician to an infectious complication [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracranial complications</strong> – Extracranial complications may include [<a href="#rid70">70,73-77</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mastoiditis (<a class="graphic graphic_picture graphicRef70910 graphicRef83205" href="/d/graphic/70910.html" rel="external">picture 3A-B</a>), which is the most common (see  <a class="medical medical_review" href="/d/html/6062.html" rel="external">"Acute mastoiditis in children: Clinical features and diagnosis", section on 'Complications'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subperiosteal abscess (see  <a class="medical medical_review" href="/d/html/6062.html" rel="external">"Acute mastoiditis in children: Clinical features and diagnosis", section on 'Complications'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Facial paralysis (see  <a class="medical medical_review" href="/d/html/6217.html" rel="external">"Facial nerve palsy in children"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Labyrinthitis (see  <a class="medical medical_review" href="/d/html/5102.html" rel="external">"Vestibular neuritis and labyrinthitis"</a>)</p><p></p><p class="bulletIndent1">Dizziness suggests a labyrinthine fistula, and facial nerve palsy suggests inflammation of the facial nerve. Subperiosteal mastoid abscesses are often associated with cholesteatoma [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracranial complications</strong> – Patients with intracranial complications often present with fever, headache, earache, vestibular symptoms, meningeal signs, and alteration in mental status [<a href="#rid73">73</a>]. Reported intracranial complications of CSOM include [<a href="#rid69">69,71,73-76,78</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Meningitis (see  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subdural, epidural, perisinus, or brain abscess (see  <a class="medical medical_review" href="/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a> and  <a class="medical medical_review" href="/d/html/103898.html" rel="external">"Intracranial epidural abscess"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lateral sinus thrombosis (see  <a class="medical medical_review" href="/d/html/3410.html" rel="external">"Septic dural sinus thrombosis"</a>)</p><p></p><p class="bulletIndent1">Brain abscess and meningitis are the most commonly reported intracranial complications [<a href="#rid74">74,78</a>]. Multiple intracranial complications can occur together. Reported mortality rates range from 3 to 19 percent [<a href="#rid73">73,78</a>].</p><p></p><p>Extracranial and intracranial complications often necessitate surgery in addition to broad-spectrum intravenous (IV) antibiotics, although the exact procedure differs depending on the complication. Consultation with a neurosurgeon may be warranted for children with clinical or radiologic evidence of an intracranial complication.</p><p>The rate of intra- and extracranial complications varies depending on risk factors in the population studied, particularly poverty. In most series, the complication rate is &lt;1 percent [<a href="#rid73">73,74,79</a>]. Extracranial complications are more common than intracranial complications, and approximately one-third of patients have two or more complications [<a href="#rid68">68,71,73</a>].</p><p>The bacteriology in complicated CSOM differs somewhat from that of uncomplicated cases, with <em>Proteus</em> being the most common isolate, followed by anaerobes and most specimens comprised of mixed flora [<a href="#rid69">69,72,74,76</a>].</p><p>The mortality in complicated CSOM ranges from 0 to 20 percent, depending on the population studied [<a href="#rid68">68,69,73,75</a>].</p><p class="headingAnchor" id="H9146213"><span class="h2">Persistent hearing loss</span><span class="headingEndMark"> — </span>CSOM is one of the most common causes of preventable hearing loss [<a href="#rid36">36,80</a>]. In one series, 90 percent of children with CSOM had permanent hearing loss of &gt;15 decibels [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Hearing loss'</a>.)</p><p>Conductive hearing loss is more common than sensorineural hearing loss (SNHL), but both may occur. The type of hearing loss is important because, while conductive hearing loss may improve with therapy and/or surgery, SNHL generally does not. Conductive hearing loss results from fluid in the middle ear and, eventually, from erosion of the ossicles, preventing conduction of the sound to the cochlea. In contrast, SNHL is thought to be due to chemical mediators and toxins that are produced by the disease process and enter the cochlea. Exposure to ototoxic medications (eg, aminoglycosides) may also play a role. In one study, the prevalence of SNHL among patients with CSOM was approximately 40 percent [<a href="#rid67">67</a>]. Reported risk factors for developing SNHL include older age, longer disease duration, larger perforations, smoking, and diabetes [<a href="#rid82">82-84</a>]. Tinnitus may be a harbinger of SNHL, and patients reporting tinnitus should be monitored closely for development of SNHL [<a href="#rid85">85</a>].</p><p>There have been few reports of cochlear implantation in patients with a history of CSOM since cochlear implants can only be placed after the disease is completely eradicated and it is not often an option in resource-limited settings [<a href="#rid86">86-89</a>]. In the reported case series, patients underwent a single procedure or a staged procedure depending on whether there was additional pathology (eg, cholesteatoma, unstable mastoid cavity) and complication rates were low, with good audiometric outcomes [<a href="#rid86">86-89</a>]. If CSOM develops in a patient with a preexisting cochlear implant, it is possible to treat the infection without removing the implant, as long as there is no cholesteatoma [<a href="#rid90">90</a>].</p><p>Treatment of hearing impairment, including the use of cochlear implants, is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6298.html" rel="external">"Hearing loss in children: Treatment", section on 'Cochlear implants'</a> and  <a class="medical medical_review" href="/d/html/6849.html" rel="external">"Hearing amplification in adults", section on 'Cochlear implants'</a>.)</p><p class="headingAnchor" id="H436418562"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The cornerstone of disease management for CSOM is prevention because the availability of different treatment modalities may be limited in many settings, failure rates are often high, and hearing loss can occur even when adequate treatment is provided. (See <a class="local">'Persistent hearing loss'</a> above.)</p><p>One of the first steps in primary disease prevention is education and knowledge about the disease process, which is lacking in much of the at-risk population [<a href="#rid91">91</a>]. CSOM frequently begins with acute otitis media (AOM). Thus, preventing and promptly and appropriately treating AOM should decrease the incidence of CSOM [<a href="#rid92">92</a>]. In theory, public health interventions that address risk factors, such as passive smoke exposure, contaminated water, and malnutrition, may also decrease rates of CSOM, although definitive proof that these measures are effective is lacking [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications"</a> and  <a class="medical medical_review" href="/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence"</a> and  <a class="medical medical_review" href="/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis", section on 'Complications of AOM'</a>.)</p><p class="headingAnchor" id="H2729333670"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109085.html" rel="external">"Society guideline links: Acute otitis media, otitis media with effusion, and external otitis"</a>.)</p><p class="headingAnchor" id="H191200377"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Chronic suppurative otitis media (CSOM), which is characterized by chronic drainage from the middle ear associated with tympanic membrane (TM) perforation (<a class="graphic graphic_picture graphicRef91415" href="/d/graphic/91415.html" rel="external">picture 1</a>), is one of the most common childhood infectious diseases worldwide. It is a leading cause of hearing impairment in resource-limited settings. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – For patients with uncomplicated CSOM without cholesteatoma, we suggest aural toilet <strong>plus</strong> an ototopical fluoroquinolone (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a>) for initial therapy rather than either intervention alone, other topical therapies, or oral antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Acceptable regimens include ofloxacin otic solution (five drops three times a day) or ciprofloxacin otic solution (0.25 mL single-dose container twice daily) for two weeks. Aural toilet is performed until the ear is consistently dry and free of debris. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment failure</strong> – For patients who fail initial therapy (defined as persistent otorrhea after approximately three weeks of initial topical treatment), we suggest culture-directed antibiotic therapy rather than other interventions, including surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Cultures should be obtained from the middle ear (ie, through the TM perforation), not from the external auditory canal. Culture-directed antibiotic therapy typically consists of a topical antibiotic, unless there is no suitable option based upon the susceptibility pattern of the isolated pathogen, in which case, an oral antibiotic is used. We generally reserve intravenous (IV) antibiotic therapy for patients who fail culture-directed topical or oral therapy. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrences</strong> – CSOM is a remitting and relapsing disease, with recurrence most common during the first several months after initial therapy. While recurrence is common, most patients are successfully treated with medical therapy alone. Evaluation and management of patients with recurrent disease includes (see <a class="local">'Recurrent disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counsel patients to follow strict water precautions. (See <a class="local">'Prevention of recurrences'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain temporal bone computed tomography (CT) to evaluate for cholesteatoma, if this has not already been performed. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without cholesteatoma who have recurrent disease despite water precautions, we suggest tympanoplasty (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also suggest tympanoplasty as a preventative measure for patients with persistent TM perforation &gt;6 to 12 months after resolution of CSOM (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgery'</a> above and <a class="local">'Surgery for persistent tympanic membrane perforation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of CSOM include extra- and intracranial spread of infection and persistent hearing loss. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Prevention is the cornerstone of disease management for CSOM because the availability of different treatment modalities may be limited in many settings, failure rates are often high, and hearing loss can occur even when adequate treatment is provided. Primary prevention is focused on promptly and appropriately treating acute otitis media (AOM), which usually precedes CSOM. In addition, public health interventions that address risk factors may also decrease rates of CSOM. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Smith AW, Hatcher J, Mackenzie IJ, et al. Randomised controlled trial of treatment of chronic suppurative otitis media in Kenyan schoolchildren. Lancet 1996; 348:1128.</a></li><li><a class="nounderline abstract_t">Elsayed Yousef Y, Abo El-Magd EA, El-Asheer OM, Kotb S. Impact of Educational Program on the Management of Chronic Suppurative Otitis Media among Children. Int J Otolaryngol 2015; 2015:624317.</a></li><li><a class="nounderline abstract_t">Doshi J, Coulson C, Williams J, Kuo M. Aural toilet in infants: how we do it. Clin Otolaryngol 2009; 34:67.</a></li><li><a class="nounderline abstract_t">Daniel SJ. Topical treatment of chronic suppurative otitis media. Curr Infect Dis Rep 2012; 14:121.</a></li><li><a class="nounderline abstract_t">Dagan R, Fliss DM, Einhorn M, et al. Outpatient management of chronic suppurative otitis media without cholesteatoma in children. Pediatr Infect Dis J 1992; 11:542.</a></li><li><a class="nounderline abstract_t">Melaku A, Lulseged S. Chronic suppurative otitis media in a children's hospital in Addis Ababa, Ethiopia. Ethiop Med J 1999; 37:237.</a></li><li><a class="nounderline abstract_t">Choi HG, Park KH, Park SN, et al. The appropriate medical management of methicillin-resistant Staphylococcus aureus in chronic suppurative otitis media. Acta Otolaryngol 2010; 130:42.</a></li><li><a class="nounderline abstract_t">Fliss DM, Dagan R, Houri Z, Leiberman A. Medical management of chronic suppurative otitis media without cholesteatoma in children. J Pediatr 1990; 116:991.</a></li><li><a class="nounderline abstract_t">Bhutta MF, Head K, Chong LY, et al. Aural toilet (ear cleaning) for chronic suppurative otitis media. Cochrane Database Syst Rev 2020; 9:CD013057.</a></li><li><a class="nounderline abstract_t">Gupta C, Agrawal A, Gargav ND. Role of Acetic Acid Irrigation in Medical Management of Chronic Suppurative Otitis Media: A Comparative Study. Indian J Otolaryngol Head Neck Surg 2015; 67:314.</a></li><li><a class="nounderline abstract_t">Aminifarshidmehr N. The management of chronic suppurative otitis media with acid media solution. Am J Otol 1996; 17:24.</a></li><li><a class="nounderline abstract_t">Thorp MA, Kruger J, Oliver S, et al. The antibacterial activity of acetic acid and Burow's solution as topical otological preparations. J Laryngol Otol 1998; 112:925.</a></li><li><a class="nounderline abstract_t">Clayton MI, Osborne JE, Rutherford D, Rivron RP. A double-blind, randomized, prospective trial of a topical antiseptic versus a topical antibiotic in the treatment of otorrhoea. Clin Otolaryngol Allied Sci 1990; 15:7.</a></li><li><a class="nounderline abstract_t">Jaya C, Job A, Mathai E, Antonisamy B. Evaluation of topical povidone-iodine in chronic suppurative otitis media. Arch Otolaryngol Head Neck Surg 2003; 129:1098.</a></li><li><a class="nounderline abstract_t">Head K, Chong LY, Bhutta MF, et al. Topical antiseptics for chronic suppurative otitis media. Cochrane Database Syst Rev 2020; 1:CD013055.</a></li><li><a class="nounderline abstract_t">Ichibangase T, Yamano T, Miyagi M, et al. Ototoxicity of Povidone-Iodine applied to the middle ear cavity of guinea pigs. Int J Pediatr Otorhinolaryngol 2011; 75:1078.</a></li><li><a class="nounderline abstract_t">Ohyama M, Furuta S, Ueno K, et al. Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. Arch Otolaryngol Head Neck Surg 1999; 125:337.</a></li><li><a class="nounderline abstract_t">Onali MA, Bareeqa SB, Zia S, et al. Efficacy of Empirical Therapy With Combined Ciprofloxacin Versus Topical Drops Alone in Patients With Tubotympanic Chronic Suppurative Otitis Media: A Randomized Double-Blind Controlled Trial. Clin Med Insights Ear Nose Throat 2018; 11:1179550617751907.</a></li><li><a class="nounderline abstract_t">Renukananda GS, U P S, George NM. Topical vs Combination Ciprofloxacin in the Management of Discharging Chronic Suppurative Otitis Media. J Clin Diagn Res 2014; 8:KC01.</a></li><li><a class="nounderline abstract_t">Baltussen R, Smith A. Cost-effectiveness of selected interventions for hearing impairment in Africa and Asia: a mathematical modelling approach. Int J Audiol 2009; 48:144.</a></li><li><a class="nounderline abstract_t">Yuen PW, Lau SK, Chau PY, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol 1994; 15:670.</a></li><li><a class="nounderline abstract_t">Couzos S, Lea T, Mueller R, et al. Effectiveness of ototopical antibiotics for chronic suppurative otitis media in Aboriginal children: a community-based, multicentre, double-blind randomised controlled trial. Med J Aust 2003; 179:185.</a></li><li><a class="nounderline abstract_t">Harris AS, Elhassan HA, Flook EP. Why are ototopical aminoglycosides still first-line therapy for chronic suppurative otitis media? A systematic review and discussion of aminoglycosides versus quinolones. J Laryngol Otol 2016; 130:2.</a></li><li><a class="nounderline abstract_t">Macfadyen CA, Acuin JM, Gamble C. Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev 2005; :CD004618.</a></li><li><a class="nounderline abstract_t">Brennan-Jones CG, Head K, Chong LY, et al. Topical antibiotics for chronic suppurative otitis media. Cochrane Database Syst Rev 2020; 1:CD013051.</a></li><li><a class="nounderline abstract_t">Chong LY, Head K, Webster KE, et al. Topical versus systemic antibiotics for chronic suppurative otitis media. Cochrane Database Syst Rev 2021; 2:CD013053.</a></li><li><a class="nounderline abstract_t">Dohar JE, Kenna MA, Wadowsky RM. In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Am J Otol 1996; 17:207.</a></li><li><a class="nounderline abstract_t">Blakley BW, Alsaleh S, Dewji Z, et al. Steroids in aminoglycoside-containing ear drops: do they reduce cochlear toxicity? Laryngoscope 2014; 124:1209.</a></li><li><a class="nounderline abstract_t">Berenholz LP, Rossi DL, Lippy WH, Burkey JM. Is there an ototoxicity risk from Cortisporin and comparable otic suspensions? Distortion-product otoacoustic emission findings. Ear Nose Throat J 2012; 91:106.</a></li><li><a class="nounderline abstract_t">Oghan F, Apuhan T, Yılmaz F. Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits. Int J Pediatr Otorhinolaryngol 2011; 75:915.</a></li><li><a class="nounderline abstract_t">Hannley MT, Denneny JC 3rd, Holzer SS. Use of ototopical antibiotics in treating 3 common ear diseases. Otolaryngol Head Neck Surg 2000; 122:934.</a></li><li><a class="nounderline abstract_t">Acuin J. Chronic suppurative otitis media. BMJ Clin Evid 2007; 2007.</a></li><li><a class="nounderline abstract_t">Panchasara A, Singh A, Mandavia D, et al. Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomised, double blind, parallel group, comparative study. Acta Otorhinolaryngol Ital 2015; 35:39.</a></li><li><a class="nounderline abstract_t">Karov I. Preoperative treatment of children with chronic suppurative otitis media. Folia Med (Plovdiv) 1996; 38:63.</a></li><li><a class="nounderline abstract_t">Brook I. The role of anaerobic bacteria in chronic suppurative otitis media in children: implications for medical therapy. Anaerobe 2008; 14:297.</a></li><li><a class="nounderline abstract_t">Mushi MF, Mwalutende AE, Gilyoma JM, et al. Predictors of disease complications and treatment outcome among patients with chronic suppurative otitis media attending a tertiary hospital, Mwanza Tanzania. BMC Ear Nose Throat Disord 2016; 16:1.</a></li><li><a class="nounderline abstract_t">Song JJ, Lee BD, Lee KH, et al. Changes in antibiotic resistance in recurrent Pseudomonas aeruginosa infections of chronic suppurative otitis media. Ear Nose Throat J 2016; 95:446.</a></li><li><a class="nounderline abstract_t">Brook I, Gober AE. Reliability of the microbiology of spontaneously draining acute otitis media in children. Pediatr Infect Dis J 2000; 19:571.</a></li><li><a class="nounderline abstract_t">Bluestone CD. Current management of chronic suppurative otitis media in infants and children. Pediatr Infect Dis J 1988; 7:S137.</a></li><li><a class="nounderline abstract_t">Kenna MA, Rosane BA, Bluestone CD. Medical management of chronic suppurative otitis media without cholesteatoma in children--update 1992. Am J Otol 1993; 14:469.</a></li><li><a class="nounderline abstract_t">Jang CH, Song CH, Wang PC. Topical vancomycin for chronic suppurative otitis media with methicillin-resistant Staphylococcus aureus otorrhoea. J Laryngol Otol 2004; 118:645.</a></li><li><a class="nounderline abstract_t">Macfadyen CA, Acuin JM, Gamble C. Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev 2006; :CD005608.</a></li><li><a class="nounderline abstract_t">Kristo B, Buljan M. Microbiology of the chronic suppurative otitis media. Med Glas (Zenica) 2011; 8:284.</a></li><li><a class="nounderline abstract_t">Lang R, Goshen S, Raas-Rothschild A, et al. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr Infect Dis J 1992; 11:925.</a></li><li><a class="nounderline abstract_t">Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol 2008; 72:647.</a></li><li><a class="nounderline abstract_t">Campos MA, Arias A, Rodriguez C, et al. Etiology and therapy of chronic suppurative otitis. J Chemother 1995; 7:427.</a></li><li><a class="nounderline abstract_t">Brook I. Management of chronic suppurative otitis media: superiority of therapy effective against anaerobic bacteria. Pediatr Infect Dis J 1994; 13:188.</a></li><li><a class="nounderline abstract_t">Park DC, Lee SK, Cha CI, et al. Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci. Eur J Clin Microbiol Infect Dis 2008; 27:571.</a></li><li><a class="nounderline abstract_t">Somekh E, Cordova Z. Ceftazidime versus aztreonam in the treatment of pseudomonal chronic suppurative otitis media in children. Scand J Infect Dis 2000; 32:197.</a></li><li><a class="nounderline abstract_t">Jang CH, Park SY. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media. Clin Otolaryngol Allied Sci 2004; 29:321.</a></li><li><a class="nounderline abstract_t">Park MK, Jung MH, Kang HJ, et al. The changes of MRSA infections in chronic suppurative otitis media. Otolaryngol Head Neck Surg 2008; 139:395.</a></li><li><a class="nounderline abstract_t">Rai AK, Singh GB, Sahu R, et al. Evaluation of simultaneous bilateral same day tympanoplasty type I in chronic suppurative otitis media. Auris Nasus Larynx 2014; 41:148.</a></li><li><a class="nounderline abstract_t">Kenna MA, Bluestone CD, Reilly JS, Lusk RP. Medical management of chronic suppurative otitis media without cholesteatoma in children. Laryngoscope 1986; 96:146.</a></li><li><a class="nounderline abstract_t">Ruhl CM, Pensak ML. Role of aerating mastoidectomy in noncholesteatomatous chronic otitis media. Laryngoscope 1999; 109:1924.</a></li><li><a class="nounderline abstract_t">Balyan FR, Celikkanat S, Aslan A, et al. Mastoidectomy in noncholesteatomatous chronic suppurative otitis media: is it necessary? Otolaryngol Head Neck Surg 1997; 117:592.</a></li><li><a class="nounderline abstract_t">Mishiro Y, Sakagami M, Takahashi Y, et al. Tympanoplasty with and without mastoidectomy for non-cholesteatomatous chronic otitis media. Eur Arch Otorhinolaryngol 2001; 258:13.</a></li><li><a class="nounderline abstract_t">Yang J, Lyu J, Wang Y, et al. Comparison of Endoscopic Cartilage Myringoplasty in Dry and Wet Ears With Chronic Suppurative Otitis Media. Ear Nose Throat J 2023; 102:NP177.</a></li><li><a class="nounderline abstract_t">Li C, Wang B, Wang X, et al. [Observation of the short-term effect of tympanoplasty（type Ⅰ） in dry and wet ears with chronic otitis media]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2021; 35:617.</a></li><li><a class="nounderline abstract_t">Yang B, Zhang L, Chen X. Evaluation and comparison of tympanoplasty efficacy with tympanic membrane perforation after chronic suppurative otitis media in dry ear with different microorganisms. Am J Otolaryngol 2021; 42:102900.</a></li><li><a class="nounderline abstract_t">Hsieh CY, Chang CJ, Sun CH, et al. Tympanoplasty With or Without Balloon Eustachian Tuboplasty for Chronic Suppurative Otitis Media With Obstructive Eustachian Tube Dysfunction. Otol Neurotol 2020; 41:1077.</a></li><li><a class="nounderline abstract_t">Li R, Wu N, Zhang J, et al. Analysis on the correlation between Eustachian tube function and outcomes of type I tympanoplasty for chronic suppurative otitis media. Acta Otolaryngol 2020; 140:664.</a></li><li><a class="nounderline abstract_t">Arguedas A, Loaiza C, Herrera JF, Mohs E. Antimicrobial therapy for children with chronic suppurative otitis media without cholesteatoma. Pediatr Infect Dis J 1994; 13:878.</a></li><li><a class="nounderline abstract_t">Leiberman A, Fliss DM, Dagan R. Medical treatment of chronic suppurative otitis media without cholesteatoma in children--a two-year follow-up. Int J Pediatr Otorhinolaryngol 1992; 24:25.</a></li><li><a class="nounderline abstract_t">Rickers J, Petersen CG, Pedersen CB, Ovesen T. Long-term follow-up evaluation of mastoidectomy in children with non-cholesteatomatous chronic suppurative otitis media. Int J Pediatr Otorhinolaryngol 2006; 70:711.</a></li><li><a class="nounderline abstract_t">Shim HJ, Park CH, Kim MG, et al. A pre- and postoperative bacteriological study of chronic suppurative otitis media. Infection 2010; 38:447.</a></li><li><a class="nounderline abstract_t">Jensen RG, Homøe P, Andersson M, Koch A. Long-term follow-up of chronic suppurative otitis media in a high-risk children cohort. Int J Pediatr Otorhinolaryngol 2011; 75:948.</a></li><li><a class="nounderline abstract_t">Thai A, Aaron KA, Kaufman AC, Santa Maria PL. Long-Term Health Utilization and Outcomes in Chronic Suppurative Otitis Media. Otolaryngol Head Neck Surg 2022; 167:341.</a></li><li><a class="nounderline abstract_t">Dubey SP, Larawin V. Complications of chronic suppurative otitis media and their management. Laryngoscope 2007; 117:264.</a></li><li><a class="nounderline abstract_t">Chotmongkol V, Sangsaard S. Intracranial complications of chronic suppurative otitis media. Southeast Asian J Trop Med Public Health 1992; 23:510.</a></li><li><a class="nounderline abstract_t">Hossain MM, Kundu SC, Haque MR, et al. Extracranial complications of chronic suppurative otitis media. Mymensingh Med J 2006; 15:4.</a></li><li><a class="nounderline abstract_t">Mostafa BE, El Fiky LM, El Sharnouby MM. Complications of suppurative otitis media: still a problem in the 21st century. ORL J Otorhinolaryngol Relat Spec 2009; 71:87.</a></li><li><a class="nounderline abstract_t">Seven H, Coskun BU, Calis AB, et al. Intracranial abscesses associated with chronic suppurative otitis media. Eur Arch Otorhinolaryngol 2005; 262:847.</a></li><li><a class="nounderline abstract_t">Kangsanarak J, Fooanant S, Ruckphaopunt K, et al. Extracranial and intracranial complications of suppurative otitis media. Report of 102 cases. J Laryngol Otol 1993; 107:999.</a></li><li><a class="nounderline abstract_t">Sharma N, Jaiswal AA, Banerjee PK, Garg AK. Complications of Chronic Suppurative Otitis Media and Their Management: A Single Institution 12 Years Experience. Indian J Otolaryngol Head Neck Surg 2015; 67:353.</a></li><li><a class="nounderline abstract_t">Yorgancılar E, Yildirim M, Gun R, et al. Complications of chronic suppurative otitis media: a retrospective review. Eur Arch Otorhinolaryngol 2013; 270:69.</a></li><li><a class="nounderline abstract_t">Rupa V, Raman R. Chronic suppurative otitis media: complicated versus uncomplicated disease. Acta Otolaryngol 1991; 111:530.</a></li><li><a class="nounderline abstract_t">Ibekwe AO, Okoye BC. Subperiosteal mastoid abscesses in chronic suppurative otitis media. Ann Otol Rhinol Laryngol 1988; 97:373.</a></li><li><a class="nounderline abstract_t">Jain A, Arora N, Meher R, et al. Intracranial complications of CSOM in pediatric patients: A persisting problem in developing countries. Int J Pediatr Otorhinolaryngol 2017; 100:128.</a></li><li><a class="nounderline abstract_t">Matanda RN, Muyunga KC, Sabue MJ, et al. Chronic suppurative otitis media and related complications at the University Clinic of Kinshasa. B-ENT 2005; 1:57.</a></li><li><a class="nounderline abstract_t">Verhoeff M, van der Veen EL, Rovers MM, et al. Chronic suppurative otitis media: a review. Int J Pediatr Otorhinolaryngol 2006; 70:1.</a></li><li><a class="nounderline abstract_t">Jensen RG, Koch A, Homøe P. The risk of hearing loss in a population with a high prevalence of chronic suppurative otitis media. Int J Pediatr Otorhinolaryngol 2013; 77:1530.</a></li><li><a class="nounderline abstract_t">Ali Zaidi SS, Pasha HA, Suhail A, Qureshi TA. Frequency of Sensorineural hearing loss in chronic suppurative otitis media. J Pak Med Assoc 2016; 66(Suppl 3):S42.</a></li><li><a class="nounderline abstract_t">Amali A, Hosseinzadeh N, Samadi S, et al. Sensorineural hearing loss in patients with chronic suppurative otitis media: Is there a significant correlation? Electron Physician 2017; 9:3823.</a></li><li><a class="nounderline abstract_t">Singer AEA, Abdel-Naby Awad OG, El-Kader RMA, Mohamed AR. Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media. Am J Otolaryngol 2018; 39:88.</a></li><li><a class="nounderline abstract_t">Mohd Salehuddin NS, Md Daud MK, Nik Othman NA, Abd Rahman N. Extended high frequency hearing loss in tinnitus-positive chronic suppurative otitis media patient. Laryngoscope Investig Otolaryngol 2021; 6:1137.</a></li><li><a class="nounderline abstract_t">El-Kashlan HK, Arts HA, Telian SA. Cochlear implantation in chronic suppurative otitis media. Otol Neurotol 2002; 23:53.</a></li><li><a class="nounderline abstract_t">Axon PR, Mawman DJ, Upile T, Ramsden RT. Cochlear implantation in the presence of chronic suppurative otitis media. J Laryngol Otol 1997; 111:228.</a></li><li><a class="nounderline abstract_t">Free RH, Falcioni M, Di Trapani G, et al. The role of subtotal petrosectomy in cochlear implant surgery--a report of 32 cases and review on indications. Otol Neurotol 2013; 34:1033.</a></li><li><a class="nounderline abstract_t">Wong MC, Shipp DB, Nedzelski JM, et al. Cochlear implantation in patients with chronic suppurative otitis media. Otol Neurotol 2014; 35:810.</a></li><li><a class="nounderline abstract_t">Baruah P, Hanvey K, Irving R, Tzifa K. Impact of Chronic Suppurative Otitis Media in Pediatric Cochlear Implant Recipients-Insight into the Challenges from a Tertiary Referral Center in UK. Otol Neurotol 2017; 38:672.</a></li><li><a class="nounderline abstract_t">Neogi R, Dan A, Maity K, et al. Clinico-epidemiological profile of chronic suppurative otitis media patients attending a tertiary care hospital. J Indian Med Assoc 2011; 109:324.</a></li><li><a class="nounderline abstract_t">Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998; 42:207.</a></li><li><a class="nounderline abstract_t">Koch A, Homøe P, Pipper C, et al. Chronic suppurative otitis media in a birth cohort of children in Greenland: population-based study of incidence and risk factors. Pediatr Infect Dis J 2011; 30:25.</a></li></ol></div><div id="topicVersionRevision">Topic 91002 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8888166" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Randomised controlled trial of treatment of chronic suppurative otitis media in Kenyan schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792984" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of Educational Program on the Management of Chronic Suppurative Otitis Media among Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260891" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aural toilet in infants: how we do it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22311665" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Topical treatment of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528644" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outpatient management of chronic suppurative otitis media without cholesteatoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961874" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic suppurative otitis media in a children's hospital in Addis Ababa, Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19424918" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The appropriate medical management of methicillin-resistant Staphylococcus aureus in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189979" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medical management of chronic suppurative otitis media without cholesteatoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926406" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aural toilet (ear cleaning) for chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405670" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of Acetic Acid Irrigation in Medical Management of Chronic Suppurative Otitis Media: A Comparative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694129" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The management of chronic suppurative otitis media with acid media solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211213" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The antibacterial activity of acetic acid and Burow's solution as topical otological preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323085" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A double-blind, randomized, prospective trial of a topical antiseptic versus a topical antibiotic in the treatment of otorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568795" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of topical povidone-iodine in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31902140" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Topical antiseptics for chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741096" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ototoxicity of Povidone-Iodine applied to the middle ear cavity of guinea pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190808" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29348711" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of Empirical Therapy With Combined Ciprofloxacin Versus Topical Drops Alone in Patients With Tubotympanic Chronic Suppurative Otitis Media: A Randomized Double-Blind Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25121008" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Topical vs Combination Ciprofloxacin in the Management of Discharging Chronic Suppurative Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19283586" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cost-effectiveness of selected interventions for hearing impairment in Africa and Asia: a mathematical modelling approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8572070" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12914507" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effectiveness of ototopical antibiotics for chronic suppurative otitis media in Aboriginal children: a community-based, multicentre, double-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26584651" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Why are ototopical aminoglycosides still first-line therapy for chronic suppurative otitis media? A systematic review and discussion of aminoglycosides versus quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235370" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31896168" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Topical antibiotics for chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33561891" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Topical versus systemic antibiotics for chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723948" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142776" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Steroids in aminoglycoside-containing ear drops: do they reduce cochlear toxicity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is there an ototoxicity risk from Cortisporin and comparable otic suspensions? Distortion-product otoacoustic emission findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592592" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10828818" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of ototopical antibiotics in treating 3 common ear diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454051" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26015650" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomised, double blind, parallel group, comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145593" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Preoperative treatment of children with chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114112" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The role of anaerobic bacteria in chronic suppurative otitis media in children: implications for medical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26766925" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predictors of disease complications and treatment outcome among patients with chronic suppurative otitis media attending a tertiary hospital, Mwanza Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792822" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Changes in antibiotic resistance in recurrent Pseudomonas aeruginosa infections of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877177" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reliability of the microbiology of spontaneously draining acute otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3217177" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Current management of chronic suppurative otitis media in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122710" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Medical management of chronic suppurative otitis media without cholesteatoma in children--update 1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15453944" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Topical vancomycin for chronic suppurative otitis media with methicillin-resistant Staphylococcus aureus otorrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437533" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849954" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Microbiology of the chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1454433" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321598" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596126" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Etiology and therapy of chronic suppurative otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8177625" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Management of chronic suppurative otitis media: superiority of therapy effective against anaerobic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299908" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10826908" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ceftazidime versus aztreonam in the treatment of pseudomonal chronic suppurative otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15270816" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18722220" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The changes of MRSA infections in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268329" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluation of simultaneous bilateral same day tympanoplasty type I in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3945144" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Medical management of chronic suppurative otitis media without cholesteatoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10591348" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Role of aerating mastoidectomy in noncholesteatomatous chronic otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419084" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mastoidectomy in noncholesteatomatous chronic suppurative otitis media: is it necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11271427" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tympanoplasty with and without mastoidectomy for non-cholesteatomatous chronic otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33719601" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of Endoscopic Cartilage Myringoplasty in Dry and Wet Ears With Chronic Suppurative Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34304491" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : [Observation of the short-term effect of tympanoplasty（typeⅠ）in dry and wet ears with chronic otitis media].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33454455" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation and comparison of tympanoplasty efficacy with tympanic membrane perforation after chronic suppurative otitis media in dry ear with different microorganisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32472920" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tympanoplasty With or Without Balloon Eustachian Tuboplasty for Chronic Suppurative Otitis Media With Obstructive Eustachian Tube Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32400245" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Analysis on the correlation between Eustachian tube function and outcomes of type I tympanoplasty for chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854886" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antimicrobial therapy for children with chronic suppurative otitis media without cholesteatoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1399301" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Medical treatment of chronic suppurative otitis media without cholesteatoma in children--a two-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225934" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term follow-up evaluation of mastoidectomy in children with non-cholesteatomatous chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20700754" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A pre- and postoperative bacteriological study of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592588" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term follow-up of chronic suppurative otitis media in a high-risk children cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34637356" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-Term Health Utilization and Outcomes in Chronic Suppurative Otitis Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277619" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Complications of chronic suppurative otitis media and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1488709" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intracranial complications of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467754" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Extracranial complications of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19145101" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Complications of suppurative otitis media: still a problem in the 21st century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15959795" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intracranial abscesses associated with chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288994" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Extracranial and intracranial complications of suppurative otitis media. Report of 102 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26693451" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Complications of Chronic Suppurative Otitis Media and Their Management: A Single Institution 12 Years Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249835" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Complications of chronic suppurative otitis media: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1887779" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chronic suppurative otitis media: complicated versus uncomplicated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3408111" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Subperiosteal mastoid abscesses in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802356" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intracranial complications of CSOM in pediatric patients: A persisting problem in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16044735" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Chronic suppurative otitis media and related complications at the University Clinic of Kinshasa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198004" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Chronic suppurative otitis media: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23906989" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The risk of hearing loss in a population with a high prevalence of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27895351" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Frequency of Sensorineural hearing loss in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28465813" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Sensorineural hearing loss in patients with chronic suppurative otitis media: Is there a significant correlation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29331307" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34667858" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Extended high frequency hearing loss in tinnitus-positive chronic suppurative otitis media patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773847" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cochlear implantation in chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156058" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cochlear implantation in the presence of chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23856625" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The role of subtotal petrosectomy in cochlear implant surgery--a report of 32 cases and review on indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569796" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cochlear implantation in patients with chronic suppurative otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333779" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impact of Chronic Suppurative Otitis Media in Pediatric Cochlear Implant Recipients-Insight into the Challenges from a Tertiary Referral Center in UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187766" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinico-epidemiological profile of chronic suppurative otitis media patients attending a tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466224" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20700079" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Chronic suppurative otitis media in a birth cohort of children in Greenland: population-based study of incidence and risk factors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
